Advancing precision medicine therapeutics for Parkinson’s utilizing a shared quantitative systems pharmacology model and framework

Keyphrases

• Biomarker Discovery 33%
• Clinical Trials 66%
• Collaborative Approach 33%
• Complex Data 33%
• Disease-modifying Therapy 100%
• Drug Development 33%
• Endolysosomal System 33%
• Gene-based 33%
• Genetic Constructs 33%
• Genetic Findings 33%
• Human Genetics 33%
• Inflammation 33%
• Leucine-rich Repeat Kinase 2 (LRRK2) 33%
• Mechanistic Model 33%
• Mitochondrial Function 33%
• Model-informed Drug Development 33%
• Modeling Strategy 33%
• Molecular Pathways 33%
• Parkinson 100%
• Parkinson's Disease 33%
• Pathophysiology 66%
• Pharmacology 33%
• Phenotypic Drug Discovery 33%
• Precision Medicine 100%
• Proof of Mechanism 33%
• Quantitative Systems Pharmacology 100%
• Regulatory Framework 33%
• Regulatory Landscape 33%
• Therapeutic Candidates 66%
• Therapeutic Strategies 33%
• Translational Model 33%
• Translational Modeling 33%

Biochemistry, Genetics and Molecular Biology

• Biomarker Discovery 50%
• Candidate Gene 50%
• Clinical Trial 100%
• Genetics 100%
• Human Genetics 50%
• LRRK2 50%
• Target Tissue 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 50%
• Clinical Trial 50%
• Diseases 100%
• Drug Development 50%
• Inflammation 25%
• Parkinson's Disease 25%
• Pathophysiology 50%
• Quantitative Systems Pharmacology Modeling 25%